menu
    • menu

    Company profile for Alnylam Pharmaceuticals

    NEW Drugs in Dev: 42
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam marked by it...
    Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alnylam PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Third Street 3rd Floor Cambridge, MA 02142
    Telephone
    Telephone
    617.551.8200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.alnylam.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alnylam-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/alnylam

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alnylam to Host Tenth
    Alnylam to Host Tenth "RNAi Roundtable" Webcast Series

    12 Jun 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260612239247/en/Alnylam-to-Host-Tenth-RNAi-Roundtable-Webcast-Series

    BUSINESSWIRE
    12 Jun 2026
    Share Share
    GENESIS Pharma Expands Alnylam RNAi Deal to Nordics Region
    GENESIS Pharma Expands Alnylam RNAi Deal to Nordics Region

    10 Jun 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260610467298/en/GENESIS-Pharma-Expands-Strategic-Commercial-Partnership-with-Alnylam-Pharmaceuticals-for-RNAi-Therapeutics-to-the-Nordic-Region

    BUSINESSWIRE
    10 Jun 2026
    Share Share
    Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
    Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

    03 Jun 2026

    // PRESS RELEASE

    https://inceptive.com/blog/alnylam-ai-rnai-therapeutics-partnership

    PRESS RELEASE
    03 Jun 2026
    Share Share
    Alnylam Issues 2025 Corporate Responsibility Report
    Alnylam Issues 2025 Corporate Responsibility Report

    19 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260519990338/en/Alnylam-Issues-2025-Corporate-Responsibility-Report

    BUSINESSWIRE
    19 May 2026
    Share Share
    Vutrisiran Shows Strong ATTR-CM Benefit at Heart Failure 2026
    Vutrisiran Shows Strong ATTR-CM Benefit at Heart Failure 2026

    12 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260511111257/en/New-Data-Analyses-Presented-at-Heart-Failure-2026-Demonstrate-Robust-and-Consistent-Clinical-Benefit-of-Vutrisiran-as-a-First-Line-Treatment-Option-Across-ATTR-CM-Patient-Populations-Including-Patients-with-a-High-Disease-Burden

    BUSINESSWIRE
    12 May 2026
    Share Share
    Alnylam to Webcast Presentations at Upcoming Investor Conferences
    Alnylam to Webcast Presentations at Upcoming Investor Conferences

    07 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260507963806/en/Alnylam-to-Webcast-Presentations-at-Upcoming-Investor-Conferences

    BUSINESSWIRE
    07 May 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search